


BAY 1135626

Cat. No.:	HY-147281
CAS No.:	1404071-37-9
Molecular Formula:	C ₅₅ H ₈₆ N ₁₀ O ₁₁
Molecular Weight:	1063.33
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody-agent conjugate (ADC), is used to non-small cell lung cancer (NSCLC) research ^[1] .																
In Vitro	<p>C4.4A (LYPD3) is a protein expressed in non-small cell lung cancer (NSCLC), with scarcely expressing in normal tissues^[1]. BAY 1135626 can be synthesized into BAY 1129980 (C4.4A-ADC), shows a strong anti-proliferative effect on C4.4A expressing cell lines^[1].</p> <p>BAY 1129980 (0.001-100 nM; 72 h) inhibits the proliferation of A549 lung cancer cell lines transfected with C4.4A^[1]. BAY 1129980 (0.001-100 nM; 72 h) exhibits high and selective efficacy on hC4.4A:A549 cells in vitro^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>hC4.4A:A549 lung cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>0.001-100 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>High potency at subnanomolar range with an IC₅₀ value of 0.05 nM. Resulted remarkable selectivity on hC4.4A:A549 with over 1,000-fold compared with mock:A549 cells.</td> </tr> </table> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>NCI-H292, FaDu, NCI-H322, SCaBER, SCC-4</td> </tr> <tr> <td>Concentration:</td> <td>0.001-100 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cancer cell growth in a dose-dependent manner.</td> </tr> </table>	Cell Line:	hC4.4A:A549 lung cancer cells	Concentration:	0.001-100 nM	Incubation Time:	72 hours	Result:	High potency at subnanomolar range with an IC ₅₀ value of 0.05 nM. Resulted remarkable selectivity on hC4.4A:A549 with over 1,000-fold compared with mock:A549 cells.	Cell Line:	NCI-H292, FaDu, NCI-H322, SCaBER, SCC-4	Concentration:	0.001-100 nM	Incubation Time:	72 hours	Result:	Inhibited cancer cell growth in a dose-dependent manner.
Cell Line:	hC4.4A:A549 lung cancer cells																
Concentration:	0.001-100 nM																
Incubation Time:	72 hours																
Result:	High potency at subnanomolar range with an IC ₅₀ value of 0.05 nM. Resulted remarkable selectivity on hC4.4A:A549 with over 1,000-fold compared with mock:A549 cells.																
Cell Line:	NCI-H292, FaDu, NCI-H322, SCaBER, SCC-4																
Concentration:	0.001-100 nM																
Incubation Time:	72 hours																
Result:	Inhibited cancer cell growth in a dose-dependent manner.																
In Vivo	<p>BAY 1129980 (1.9-7.5 mg/kg; i.v.; 20 d) inhibits tumor growth in vivo in mouse^[1]. BAY 1129980 with a repeated dosing (15 mg/kg; i.v.; 21 d for 1st cycle and 57 d for 2nd cycle) is well tolerated without changing the sensitivity to the treatment^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																

Animal Model:	C4.4A-positive NCI-H292 NSCLC xenograft mouse model ^[1]
Dosage:	1.9, 3.75, 7.5 mg/kg
Administration:	Intravenous injection; 20 days
Result:	Halted tumor growth on day 20 dose dependently, as the monotherapy treatment, with a minimum effective dose (MED) of 1.9 mg/kg.
Animal Model:	C4.4A-positive NCI-H292 NSCLC xenograft mouse model ^[1]
Dosage:	15 mg/kg
Administration:	Intravenous injection; 21 days for the first cycle treatment, 57 days for the second cycle treatment
Result:	Reduced tumor volume with a marked delay of tumor growth. Demonstrated well tolerance, still left regrown tumors sensitive to treatment.

REFERENCES

[1]. Willuda J, et al. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. *Mol Cancer Ther.* 2017 May. 16(5):893-904.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA